Shareholder Class Action

Shareholders say in a <strong><a href="http://www.courthousenews.com/wp-content/uploads/2018/07/Shareholder.CA_.pdf">federal class action</a></strong> that they lost more than $100 million when Abbvie biopharmaceuticals announced it was buying back up to $7.5 billion of its own shares in a modified Dutch auction at $105 a share, but after the market closed, revealed that the price was only $103 a share.

CHICAGO — Shareholders say in a federal class action that they lost more than $100 million when Abbvie biopharmaceuticals announced it was buying back up to $7.5 billion of its own shares in a modified Dutch auction at $105 a share, but after the market closed, revealed that the price was only $103 a share.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.